Related Experiment Video
Updated: Jan 23, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Future directions in soft tissue sarcoma treatment
Francis Hall1, Victor Villalobos1, Breelyn Wilky1
1Department of Internal Medicine, Division of Medical Oncology, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado.
Abstract:
Sarcoma is a broad term for mesenchymal malignancies that arise from soft tissue or bone. Despite classification by histologic subtype, clinical behavior and response to therapy have great variability. Modern genetic sequencing techniques have been able to identify additional genetic variability and subsequently new targeted therapies. In this review, we discuss the current state of STS diagnostics and treatment and explore some of the more promising areas in which progress is being made. We discuss therapies targeting PDGFRα/KIT, β-Catenin/APC/NOTCH, IDH-1/2 mutations, MDM2 amplifications, EZH2/INI1 expression loss, ALK fusion, and ASPSCR1-TFE3 fusion. We also discuss the progress that has been made within immunotherapies. While soft tissue sarcomas still portend a poor prognosis, these targeted therapies and immunotherapies provide treatment with less toxic side effects.
Insights
New targeted therapies and immunotherapies offer improved treatment options for soft tissue sarcomas (STS), addressing genetic variability and reducing toxic side effects despite poor prognoses.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Sarcomas are diverse mesenchymal malignancies with variable clinical behavior.
- Histologic subtypes alone do not fully capture the heterogeneity of sarcoma.
- Advances in genetic sequencing reveal molecular variability, enabling targeted therapies.
Purpose of the Study:
- To review the current diagnostic and therapeutic landscape of soft tissue sarcomas (STS).
- To explore emerging targeted therapies and immunotherapies for STS.
- To highlight progress in precision medicine for sarcoma treatment.
Main Methods:
- Review of current literature on STS diagnostics and treatment.
- Discussion of genetic alterations and their targeted therapies.
- Exploration of advancements in sarcoma immunotherapy.
Main Results:
- Identification of key molecular targets including PDGFRα/KIT, β-Catenin/APC/NOTCH, IDH-1/2, MDM2, EZH2/INI1, ALK, and ASPSCR1-TFE3.
- Progress in the development and application of immunotherapies for STS.
- Emerging therapies show promise in managing STS with potentially fewer side effects.
Conclusions:
- Targeted therapies and immunotherapies represent a significant advancement in STS treatment.
- These novel approaches offer more precise treatment strategies compared to traditional methods.
- Despite persistent challenges, these advancements provide hope for improved patient outcomes in STS.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Directing Effect of Substituents: meta-Directing Groups
Directing Effect of Substituents: ortho–para-Directing Groups
Directional Relays
Directional Terms
Direct Motor Pathways
The corticospinal tract is responsible for the voluntary movement of the limbs and trunk. It originates in the cerebral cortex of the brain and descends through the cerebrum's internal capsule and...

